Eli Lilly has become one of the most closely watched stocks in big pharma after a strong multi year run, and the key question now is whether the cash the business can generate actually supports where the share price has ended up. With expectations anchored to obesity, diabetes and a growing pipeline across other therapies, investors are increasingly focusing on what the current valuation assumes about Lilly's future cash flows.
- Over the past 5 years the stock has delivered a very large total return of about 474%, which puts a lot of weight on whether the underlying cash generation can live up to what the market is already pricing in.
- Recent momentum around drugs like Mounjaro, Zepbound and Foundayo, plus Lilly's push into areas such as neurodegenerative disease and oncology, can support expectations for stronger long term cash flows but also concentrates the valuation on a relatively narrow set of high profile assets and programs.
- What if you looked at Eli Lilly through its earnings instead? See what Eli Lilly's 46.4x P/E says about the price.
The stock's next move may depend on whether the current price fairly reflects the intrinsic value suggested by Eli Lilly's cash flows under a Discounted Cash Flow (DCF) view.
If you want to explore the same cash flow question beyond Eli Lilly, apply the rule to a wider set of 32 high quality undervalued stocks.
Is Eli Lilly a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach here projects the cash Eli Lilly can return to shareholders and then compares that stream with the current market price. On this view, the model suggests Eli Lilly’s estimated intrinsic value sits meaningfully above where the shares trade today at $1,437.29. The latest twelve month free cash flow is about $13.9b in $ terms, which gives the model a substantial base of current cash generation to work from rather than a purely story driven forecast.
Looking out across the two stage free cash flow to equity model, the projections build in growing free cash flow through the next decade, consistent with analysts expecting larger absolute cash pools by 2030 and beyond. Because much of that expected cash relies on obesity and diabetes therapies plus newer areas like oncology and neurodegenerative disease, the DCF is effectively a check on how much of today’s price already reflects those pipelines. The strong 2026 update, where management raised revenue guidance on Mounjaro and Zepbound strength, fits with the growth assumption embedded in those cash flow estimates and helps explain why the model still places intrinsic value meaningfully above the market price. Find out what Eli Lilly could be worth using our Discounted Cash Flow (DCF) estimate.
The Eli Lilly Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Eli Lilly extend the cash flow puzzle into concrete storylines about what would need to happen to growth, profitability and earnings for the stock to be worth materially more or less than today’s price. Each narrative links its numbers to a clear view on where Eli Lilly's growth profile, margins and key risks go next, so you can return to that thesis as new information arrives on the Community page.
The two Eli Lilly stories are not miles apart, but one side sees extra upside in the cash flows while the other leans toward caution on the current tag.
Bull case: roughly fairly valued
According to AHaron, an investor in the Simply Wall St Community, the stronger view on Eli Lilly hinges on what the pipeline could add to future cash flows.
"Lilly has a next-generation weight loss drug called retatrutide currently completing its final round of clinical trials, and it works differently from everything on the market today…"
Discover why this Narrative puts Eli Lilly at roughly fairly valued.
Bear case: 21% overvalued
eat_dis_watermelon, a Simply Wall St Community investor who wrote the bearish view, focuses more on what might cap returns from Eli Lilly at today’s valuation.
"GLP-1 drugs are priced at $900-110 per month in the USA, which might be too much for most of the target market in the USA and overseas…"
Explore why this Narrative puts Eli Lilly at 21% overvalued.
Before acting on Eli Lilly's valuation, there is one more factor to weigh
Price and cash flows only tell part of the Eli Lilly story, because Simply Wall St's broader checks have also flagged specific concerns that deserve attention before you decide what to do next. Take a closer look at 2 warning signs (1 major) before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com